OCT SoCal 2026: AI Know-How, Responsible Use, and Taking Ownership
OVERVIEWThe 2026 OCT (Oncology Clinical Trials) SoCal conference addressed AI's role in clinical trial design and operations, with emphasis on responsible AI use and institutional ownership. Key themes included: AI's potential to accelerate trial enrollment and streamline operations; the need for governance frameworks; and the importance of clinician leadership in AI implementation. Speakers highlighted that AI's value in clinical trials depends on responsible deployment—including transparency about AI limitations, validation of AI recommendations against clinical judgment, and clear accountability when AI systems make errors. The conference reflected growing recognition that AI governance must accompany AI adoption. OCT SoCal 2026 represented a maturation of clinical trials' AI conversation: from exploring whether AI could help to establishing how to use AI responsibly. This shift reflects both AI's demonstrated value and the governance challenges that have emerged as deployments have scaled. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.